GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harrow Inc (NAS:HROW) » Definitions » Shiller PE Ratio

Harrow (Harrow) Shiller PE Ratio : (As of May. 01, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Harrow Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Harrow Shiller PE Ratio Historical Data

The historical data trend for Harrow's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harrow Shiller PE Ratio Chart

Harrow Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Harrow Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Harrow's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Harrow's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harrow's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Harrow's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Harrow's Shiller PE Ratio falls into.



Harrow Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Harrow's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Harrow's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.27/129.4194*129.4194
=-0.270

Current CPI (Dec. 2023) = 129.4194.

Harrow Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.260 99.695 -0.338
201406 -0.280 100.560 -0.360
201409 -0.270 100.428 -0.348
201412 -0.300 99.070 -0.392
201503 -0.330 99.621 -0.429
201506 -0.390 100.684 -0.501
201509 -0.410 100.392 -0.529
201512 -0.530 99.792 -0.687
201603 -0.430 100.470 -0.554
201606 -0.350 101.688 -0.445
201609 -0.290 101.861 -0.368
201612 -0.450 101.863 -0.572
201703 -0.260 102.862 -0.327
201706 0.060 103.349 0.075
201709 -0.280 104.136 -0.348
201712 -0.130 104.011 -0.162
201803 -0.170 105.290 -0.209
201806 0.110 106.317 0.134
201809 -0.120 106.507 -0.146
201812 0.770 105.998 0.940
201903 0.430 107.251 0.519
201906 -0.090 108.070 -0.108
201909 -0.450 108.329 -0.538
201912 0.110 108.420 0.131
202003 -0.500 108.902 -0.594
202006 -0.010 108.767 -0.012
202009 0.320 109.815 0.377
202012 0.040 109.897 0.047
202103 0.010 111.754 0.012
202106 -0.110 114.631 -0.124
202109 -0.310 115.734 -0.347
202112 -0.270 117.630 -0.297
202203 -0.090 121.301 -0.096
202206 -0.230 125.017 -0.238
202209 -0.240 125.227 -0.248
202212 0.040 125.222 0.041
202303 -0.220 127.348 -0.224
202306 -0.140 128.729 -0.141
202309 -0.130 129.860 -0.130
202312 -0.270 129.419 -0.270

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Harrow  (NAS:HROW) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Harrow Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Harrow's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Harrow (Harrow) Business Description

Traded in Other Exchanges
N/A
Address
102 Woodmont Boulevard, Suite 610, Nashville, TN, USA, 37205
Harrow Inc is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans each year.
Executives
Mark L Baum director, 10 percent owner, officer: Chief Executive Officer C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Martin A. Makary director 102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Van Horn R. Lawrence director 354 COOL SPRINGS BLVD., SUITE 106, FRANKLIN TN 37067
Andrew Boll officer: VP, Accounting and Reporting 437 S HWY 101, STE 209, SOLANA BEACH CA 92075
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391
Perry J. Sternberg director 102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Teresa Sparks director 40 BURTON HILLS BOULEVARD SUITE 500, NASHVILLE TN 37215
Robert J Kammer director, 10 percent owner, officer: Chairman of the Board 1440 28TH STREET, SUITE 9, BOULDER CO 80303
Longboard Capital Advisors, Llc other: Institutional Investor 9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212
Brett Conrad other: Managing Mbr of Longboard Cap. 1312 CEDAR ST., SANTA MONICA CA 90405
Clayton D Edwards officer: Chief Operating Officer 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Anthony Principi director 2300 WEST PLANO PARKWAY, M/S D2420, PLANO TX 75244
Donald Paul Miloni 10 percent owner 1425 GREENWOOD LANE, GREENWOOD VILLAGE CO 80125
John P. Saharek officer: Chief Commercial Officer 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130

Harrow (Harrow) Headlines

From GuruFocus

Harrow Launches VIGAMOX� in the U.S.

By Business Wire 07-31-2023

Harrow Launches ILEVRO�, NEVANAC�, and MAXIDEX� in the U.S.

By Business Wire Business Wire 05-02-2023